SynthesisBMC public health2022
A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development.
Synthesis in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Rethinking immune studies: population-level immune variations and the path forward.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Pooled it
- Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives.Frontiers in cellular and infection microbiology · 2026Pooled it
- Pooled it
- Development and Initial Analytical Evaluation of a Multiplex PCR-Based Targeted NGS Assay for Expanded Viral Detection in Clinical Respiratory Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Socio-Demographic and Prenatal Care Factors Associated with TORCH Screening During Pregnancy in Romania: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus.Scientific reports · 2026Article
- A Predictive Model for Cytomegalovirus Infection Using Routine Hematological and Biochemical Parameters:Saudi medical journal · 2026Article
- Cytomegalovirus and HIV Co-Infections During Pregnancy and Early Childhood.Current HIV/AIDS reports · 2026Review
- Cytomegalovirus congenital infection awareness, knowledge, and attitude towards prenatal screening among Jordanian women: a cross-sectional study.BMC pregnancy and childbirth · 2026Article
- Public Health Implications of High Cytomegalovirus Seroprevalence in Pregnancy: A Cross-Sectional Study in Western Uganda.Public health challenges · 2026Article
- Article
- Serological evidence linking viral infections to incident risk of hip and knee osteoarthritis.Bone & joint research · 2026Article
- Impact of Maternal Valaciclovir Therapy on Early Neurodevelopment in Congenital CMV Infection: A Retrospective Pilot Study.Children (Basel, Switzerland) · 2026Article
- Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure.JHEP reports : innovation in hepatology · 2026Article
- Seroprevalence of cytomegalovirus in individuals on antiretroviral therapy in a Nigerian tertiary hospital.BMC infectious diseases · 2026Article
- Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.The Journal of general virology · 2026Article
- Recent Trends in Cytomegalovirus IgG Seropositivity in the Adult Population of Korea: a Cross-Sectional Study and Literature Review.Annals of laboratory medicine · 2026Review
- Review
- Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults.Intensive care medicine experimental · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) is a common pathogen that affects individuals of all ages and establishes lifelong latency. Although CMV is typically asymptomatic in healthy individuals, infection during pregnancy or in immunocompromised individuals can cause severe disease. Currently, treatments are limited, with no prophylactic vaccine available. Knowledge of the current epidemiologic burden of CMV is necessary to understand the need for treatment and prevention. A systematic literature review (SLR) was conducted to describe the most recent epidemiologic burden of CMV globally.
methodsMedline, Embase, and LILACS were searched to identify data on CMV prevalence, seroprevalence, shedding, and transmission rates. The SLR covered the time period of 2010-2020 and focused geographically on Australia, Europe, Israel, Japan, Latin America (LATAM), and North America. Studies were excluded if they were systematic or narrative reviews, abstracts, case series, letters, or correspondence. Studies with sample sizes < 100 were excluded to focus on studies with higher quality of data.
resultsTwenty-nine studies were included. Among adult men, CMV immunoglobulin G (IgG) seroprevalence ranged from 39.3% (France) to 48.0% (United States). Among women of reproductive age in Europe, Japan, LATAM, and North America, CMV IgG seroprevalence was 45.6-95.7%, 60.2%, 58.3-94.5%, and 24.6-81.0%, respectively. Seroprevalence increased with age and was lower in developed than developing countries, but data were limited. No studies of CMV immunoglobulin M (IgM) seroprevalence among men were identified. Among women of reproductive age, CMV IgM seroprevalence was heterogenous across Europe (1.0-4.6%), North America (2.3-4.5%), Japan (0.8%), and LATAM (0-0.7%). CMV seroprevalence correlated with race, ethnicity, socioeconomic status, and education level. CMV shedding ranged between 0% and 70.2% depending on age group. No findings on CMV transmission rates were identified.
conclusionsCertain populations and regions are at a substantially higher risk of CMV infection. The extensive epidemiologic burden of CMV calls for increased efforts in the research and development of vaccines and treatments.
trial registrationN/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.